One hundred ASA grade I and II patients in the age group of 18 to 60 years of either sex undergoing lower abdominal or lower limb surgeries under combined spinal epidural anaesthesia (CSEA) using 0.5% bupivacaine were studied for efficacy of polygeline preloading as compared to equal volume of ringer's lactate for prevention of hypotension. They were randomly divided in two groups of 50 each. G…
Dyspepsia is one of numerous general complaints, which is commonly encountered by doctors of various disciplines. In daily practice, the complaint is not only limited for gastroenterologists. Knowledge on pathophysiology of dyspepsia have been developing continuously since a scientific investigation has been started in 1980’s, which considers Helicobacter pylori as one of key factor in managi…
The Rome III consensus committee defined dyspepsia as the presence of any of the following symptoms: postprandial fullness, early satiation, epigastric pain, and epigastric burning. Episodes of dyspepsia (Greek dys: bad, peptein: digestion) occur occasionally in every individual, but the entity of functional (“non-ulcer”) dyspepsia is a more chronic condition, present for at least 3 months…
The aim of this study was to assess systematically the efficacy of proton pump inhibitors (PPIs) in the treatment of functional dyspepsia compared with placebo and to determine if any difference in the response exists between symptom subgroups of functional dyspepsia.
Proton pump inhibitors are effective for the healing of oesophagitis. Standard doses of omeprazole, lansoprazole or pantoprazole are suf®cient for healing in mild to moderate cases of oesophagitis.
The acute and long-term effects of omeprazole on gastric acid secretion were examined in 11 patients with Zollinger-Ellison syndrome. Basal gastric acid secretion was inhibited by 50% 3 h after a single 60-mg dose of omeprazole and 78% 4 h after administration of omeprazole. Patients were treated with a single daily dose of omeprazole, and the dose requirement was defined as the lowest dose of…
The worldwide pandemic of 2019 novel coronavirus disease (COVID-19) has posed the most substantial and severe public health issue for several generations, and therapeutic options have not yet been optimised. Vitamin D (in its “parent” form, cholecalciferol) has been proposed in the pharmacological management of COVID-19 by various sources. We aimed to determine whether COVID-19 mortality wa…